Key result
The re-designed Aveir single chamber leadless pacemaker was evaluated for safety and efficacy in a first-in-human phase 2 worldwide clinical trial.
Why the study?
A redesigned single-chamber leadless pacemaker was developed to improve the safety and performance of its predecessor.
Does the re-designed Aveir single chamber leadless pacemaker provide safety and efficacy in a first-in-human clinical trial?
Does the re-designed Aveir single chamber leadless pacemaker provide safety and efficacy in a first-in-human clinical trial?
The LEADLESS II-Phase 2 trial evaluates the safety and efficacy of the re-designed Aveir single chamber leadless pacemaker in a first-in-human worldwide study.
A re-designed single chamber leadless pacemaker (LP; Aveir) was developed with the goal of improving safety and performance of its predecessor (Nanostim). Herein, we present the first-in-human expe...
No takes yet. Share an insight, caveat, or question.
Reddy et al. (2021) studied this question. The re-designed Aveir single chamber leadless pacemaker was evaluated for safety and efficacy in a first-in-human phase 2 worldwide clinical trial.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: